Discover Dr. Roy Baynes’ playbook for advancing cancer breakthroughs: strategy, teams, and patient focus from lab to clinic and beyond.
How do world-changing cancer treatments go from concept to reality?
In this episode of the Oncology Voice Network Podcast, host Dr. Kirk Shepard welcomes Dr. Roy Baynes, the Chief Medical Officer of ICON Therapeutics and the architect behind the clinical strategy for Keytruda (pembrolizumab), one of the most transformative cancer therapies of our time.
Listen as Dr. Baynes shares his personal journey from academia to industry, his leadership and collaboration philosophy, and the critical decisions that accelerated one drug to impact millions. He reveals how adaptive trials, bold partnerships, clear strategy, and relentless patient focus set new standards—not only for science, but for access and equity in cancer care.
From lessons learned at Amgen, Gilead, and Merck, to navigating regulatory relationships and cross-functional teamwork, this episode is a masterclass in what it takes to drive rapid oncology innovation. Dr. Baynes also looks ahead to the future, sharing his optimism for breakthroughs, actionable insights for teams, and why patient-centered purpose should lead every step.
Tune in and discover how strategy, leadership, and heart unite to change lives in oncology—listen now.
Follow Us
Presented by Oncology Voice Network
www.oncologyvoicenetwork.com